Jui-Wen Huang
Overview
Explore the profile of Jui-Wen Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Su J, Chiang H, Tseng P, Tai W, Hsu C, Li Y, et al.
Carcinogenesis
. 2014 Oct;
35(12):2807-14.
PMID: 25322871
Regulatory factor X-1 (RFX-1) is a transcription factor that has been linked to negative regulation of tumor progression; however, its biological function and signaling cascades are unknown. Here, we performed...
12.
Fan L, Teng H, Shiau C, Lin H, Hung M, Chen Y, et al.
Oncotarget
. 2014 Jul;
5(15):6243-51.
PMID: 25071018
Regorafenib is an inhibitor of multiple protein kinases which exerts antitumor and antimetastatic activities in metastatic colorectal cancer (CRC). SH2 domain-containing phosphatase 1 (SHP-1) is reported to have tumor suppressive...
13.
Su J, Tseng P, Hsu C, Tai W, Huang J, Ko C, et al.
Oncotarget
. 2014 Jun;
5(13):4909-19.
PMID: 24952874
Obatoclax is a small molecule which targets the Bcl-2 family, and is to treat leukemia, lymphoma and lung carcinoma. Previously, an obatoclax analogue, SC-2001, was found to disrupt the protein-protein...
14.
Tai W, Shiau C, Li Y, Chang C, Huang J, Hsueh T, et al.
J Hepatol
. 2014 Mar;
61(1):89-97.
PMID: 24657398
Background & Aims: Nintedanib, a triple angiokinase inhibitor, is currently being evaluated against advanced HCC in phase I/II clinical trials. Here, we report the underlying molecular mechanism by which nintedanib...
15.
Yip K, Zhang Z, Sakemura-Nakatsugawa N, Huang J, Vu N, Chiang Y, et al.
PLoS One
. 2014 Mar;
9(2):e89889.
PMID: 24587102
Uroporphyrinogen decarboxylase (UROD) catalyzes the conversion of uroporphyrinogen to coproporphyrinogen during heme biosynthesis. This enzyme was recently identified as a potential anticancer target; its inhibition leads to an increase in...
16.
Tai W, Shiau C, Li Y, Chen Y, Chu P, Huang J, et al.
Mol Cancer Ther
. 2013 Nov;
13(1):27-36.
PMID: 24275147
Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma. Here, we report that SC-60, a dimer-based sorafenib derivative, overcomes the resistance of sorafenib and shows a better anti-hepatocellular...
17.
Wang Y, Lin C, Shih K, Huang J, Tang C
Bioorg Med Chem Lett
. 2013 Oct;
23(23):6286-91.
PMID: 24144850
Damage to DNA is caused by ionizing radiation, genotoxic chemicals or collapsed replication forks. When DNA is damaged or cells fail to respond, a mutation that is associated with breast...
18.
Tai W, Shiau C, Chen P, Chu P, Huang H, Liu C, et al.
Hepatology
. 2013 Aug;
59(1):190-201.
PMID: 23908138
Unlabelled: Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma (HCC). Here, we report that Src homology region 2 (SH2) domain-containing phosphatase 1 (SHP-1) is a major target...
19.
Su J, Chen K, Chen W, Liu C, Huang J, Tai W, et al.
Eur J Med Chem
. 2012 Sep;
56:127-33.
PMID: 22982119
Obatoclax is a linear oligopyrrole compound which antagonizes the antiapoptotic effects of the Bcl-2 family. Herein we describe the synthesis of obatoclax derivatives by replacement of the pyrrole and indole...
20.
Chen K, Pao K, Su J, Chou Y, Liu C, Chen H, et al.
Bioorg Med Chem
. 2012 Sep;
20(20):6144-53.
PMID: 22980218
Cancerous inhibitor of PP2A (CIP2A) is a novel human oncoprotein that inhibits PP2A, contributing to tumor aggressiveness in various cancers. Several studies have shown that downregulation of CIP2A by small...